pSivida Corp. (PSDV) ,,,,, un GIOIELLO !!! (1 Viewer)
- Creatore Discussione acqua+
- Data di Inizio
Netzach
Forumer storico
Pazientare ...
coxy
coxy
Alimerare....
DickSIM
Prima o poi....ci becco!
IPO? why? nn capisco......semmai ....takeover se qualcuno è interessato.....
altrimenti..Alimera .....take the initiative.........FDA filing.
psdv ...........wait
coxy
coxy
semmai ....takeover se qualcuno è interessato.....
altrimenti..Alimera .....take the initiative.........FDA filing.
psdv ...........wait
Alimera, mi sembra stia facendo un'ipo. Ricordi di qualche mese fa'.
SE l'ipo va in porto(il che non e' detto oggi come e' oggi) l'ipo,
allora cash a psivida e filing.
Se non va bene...beh, abbiamo un problema
coxy
coxy
non ricordavo male. dal 2 novembre sono quasi 4 mesi (ci sono Credite Suisse ed Oppenheimer Funds...as usual)
IPO News Archive
Alimera Sciences files for an $80 million IPO
11/2/09
Alimera Sciences, which is a biopharmaceutical company that focuses on developing products that treat retina-related diseases, filed last Friday with the SEC to raise up to $80 million in an initial public offering. The Alpharetta, GA-based company, which was founded in 2003, plans to list on the NASDAQ under the symbol ALIM. Credit Suisse, Citi, Cowen & Company and Oppenheimer are the underwriters on the deal. No pricing terms were disclosed.
IPO News Archive
Alimera Sciences files for an $80 million IPO
11/2/09
Alimera Sciences, which is a biopharmaceutical company that focuses on developing products that treat retina-related diseases, filed last Friday with the SEC to raise up to $80 million in an initial public offering. The Alpharetta, GA-based company, which was founded in 2003, plans to list on the NASDAQ under the symbol ALIM. Credit Suisse, Citi, Cowen & Company and Oppenheimer are the underwriters on the deal. No pricing terms were disclosed.
DickSIM
Prima o poi....ci becco!
è vero......... mi scuso, avevo perso questa news.......nn di poco conto...
so, w&s
Vuze
Forumer attivo
brevemente cosa dice?
sono al lavoro e non posso mettermi a studiarlo
viralic
Forumer storico
8:33AM pSivida reports presentation of additional "positive" 24-month data from Iluvien Phase 3 FAME study for diabetic macular edema at angiogenesis 2010 (PSDV) 3.28 : Co announces 24-month data from the FAME Phase 3 study for Iluvien presented at Angiogenesis 2010 included additional efficacy and safety data that reinforced the positive top-line results reported in December 2009 by pSivida and its licensee, Alimera Sciences, Inc. Peter A. Campochiaro, MD, of The Johns Hopkins University School of Medicine, presented the 24-month results from the FAME study at the Angiogenesis 2010 meeting in Miami based on analysis of the Full Analysis Set representing all randomized patients. As previously reported, the difference in the percentage of patients in this dataset whose best corrected visual acuity improved by 15 or more letters from baseline on the Early Treatment Diabetic Retinopathy Study eye chart at month 24 was statistically significant for both doses of Iluvien in each of the two trials composing the FAME Study as well as on a combined basis. For the combined analysis, 28.7% of patients treated with low dose Iluvien, and 28.6% of patients treated with high dose gained at least 15 letters, compared with 16.2% of control patients, p = 0.002 for high and low dose. Based on the 24-month data, Alimera previously announced that it intends to file a New Drug Application for regulatory approval of the Iluvien low-dose in Q2 calendar 2010.